BCV
CRL icon

Banque Cantonale Vaudoise’s Charles River Laboratories CRL Stock Holding History

Banque Cantonale Vaudoise’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$495K Sell
2,183
-73
-3% -$13K 0.07% 121
2026
Q1 		$389K Sell
2,256
-62
-3% -$11.5K 0.01% 533
2025
Q4 		$462K Buy
2,318
+26
+1% +$4.72K 0.02% 462
2025
Q3 		$359K Sell
2,292
-197
-8% -$31.3K 0.01% 487
2025
Q2 		$378K Sell
2,489
-73
-3% -$9.73K 0.02% 472
2025
Q1 		$386K Buy
+2,562
New +$430K 0.02% 482
2024
Q3 		$425K Sell
2,159
-73
-3% -$15.2K 0.02% 406
2024
Q2 		$461K Buy
2,232
+215
+11% +$48.7K 0.02% 447
2024
Q1 		$547K Buy
2,017
+126
+7% +$30.1K 0.02% 415
2023
Q4 		$447K Sell
1,891
-820
-30% -$161K 0.02% 463
2023
Q3 		$532K Sell
2,711
-44
-2% -$9.03K 0.03% 471
2023
Q2 		$579K Buy
2,755
+191
+7% +$38K 0.03% 460
2023
Q1 		$517K Sell
2,564
-27
-1% -$6.12K 0.03% 442
2022
Q4 		$565K Buy
2,591
+36
+1% +$7.86K 0.03% 421
2022
Q3 		$502K Sell
2,555
-31
-1% -$6.69K 0.03% 480
2022
Q2 		$553K Sell
2,586
-41
-2% -$10K 0.03% 466
2022
Q1 		$746K Sell
2,627
-2,263
-46% -$698K 0.03% 458
2021
Q4 		$1.84M Sell
4,890
-380
-7% -$148K 0.07% 259
2021
Q3 		$2.17M Buy
5,270
+244
+5% +$101K 0.09% 212
2021
Q2 		$1.86M Buy
5,026
+2,268
+82% +$757K 0.08% 248
2021
Q1 		$799K Sell
2,758
-566
-17% -$157K 0.04% 425
2020
Q4 		$831K Buy
3,324
+433
+15% +$103K 0.05% 351
2020
Q3 		$655K Buy
2,891
+35
+1% +$7.26K 0.04% 369
2020
Q2 		$498K Buy
2,856
+275
+11% +$43.9K 0.04% 387
2020
Q1 		$326K Sell
2,581
-250
-9% -$37.5K 0.03% 485
2019
Q4 		$432K Buy
+2,831
New +$392K 0.03% 516

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Banque Cantonale Vaudoise's CRL Position: Q2 2026 in Review

Banque Cantonale Vaudoise reduced its Charles River Laboratories (CRL) stake by 3.2% in Q2 2026, selling an estimated $13K and leaving 2,183 shares worth $495K. The position accounts for 0.07% of the portfolio, ranked #121.

Banque Cantonale Vaudoise first reported a position in CRL in Q4 2019 and has held it in 26 quarters since. The position peaked at $2.17M in Q3 2021. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Banque Cantonale Vaudoise held 2,183 shares of Charles River Laboratories worth $495K as of Q2 2026.
  • Banque Cantonale Vaudoise sold 73 Charles River Laboratories shares in Q2 2026, an estimated $13K.
  • Charles River Laboratories made up 0.07% of Banque Cantonale Vaudoise's portfolio in Q2 2026, its #121 holding.
  • Banque Cantonale Vaudoise first reported a position in Charles River Laboratories in Q4 2019 and has held it in 26 quarters since.
  • Banque Cantonale Vaudoise's Charles River Laboratories position peaked at $2.17M in Q3 2021.
  • 570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Banque Cantonale Vaudoise's 13F filing for Q2 2026, filed 31 Jul 2026.